Coagulation Testing in Veterinary Medicine: A Practical Guide

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Conventional coagulation tests (PT, aPTT) assess the secondary hemostasis phase using platelet-poor plasma and are insensitive to hypercoagulable states or fibrinolysis disorders; viscoelastic methods (TEG, ROTEM) evaluate global hemostasis in whole blood, detecting hypercoagulability and clot dynamics.
• Preanalytical variables are critical; correct citrate anticoagulant volume (9:1 blood:citrate) is essential, and underfilled tubes artifactually prolong clotting times, while hemolyzed, lipemic, or clotted samples must be rejected.
• PT prolongation indicates extrinsic and common pathway defects (e.g., rodenticide toxicity, vitamin K deficiency, liver failure), while aPTT prolongation suggests intrinsic and common pathway issues (e.g., hemophilia, heparin therapy, DIC).
• Thrombocytopenia can cause bleeding independently of coagulopathy; for example, acute bovine viral diarrhea virus infection in cattle can lead to severe thrombocytopenia and hemorrhage without evidence of DIC.
• Sample stability varies; in canine plasma at 4°C, aPTT prolongs significantly after 72 hours, while PT and fibrinogen remain stable for up to 96 hours, necessitating prompt analysis or appropriate freezing.
• Hypercoagulability, often seen in conditions like canine hyperadrenocorticism, is not detected by PT or aPTT and requires viscoelastic testing for assessment, as conventional tests only identify hypocoagulable states.

Coagulation testing in veterinary practice spans a spectrum from single bedside assays to comprehensive laboratory panels. This article provides a practical framework for selecting, performing, and interpreting coagulation tests across species, with emphasis on the diagnostic reasoning that distinguishes bleeding disorders, hypercoagulable states, and sample artifacts. The intended reader is the practicing veterinarian who encounters coagulopathic patients in emergency, referral, or general practice settings and needs a structured approach to test choice and result interpretation.

The article covers preanalytical variables, conventional clotting times, viscoelastic methods, platelet function testing, and the interpretation of coagulation panels in common clinical scenarios. It does not provide detailed factor analysis or species-specific reference intervals, which must be obtained from the laboratory performing the assays. Where evidence is limited or contested, this is stated explicitly.

At a Glance

Physiology of Hemostasis and Test Design

Hemostasis proceeds through primary platelet plug formation, secondary fibrin clot generation via the coagulation cascade, and tertiary fibrinolysis. Conventional coagulation tests interrogate only the secondary phase using platelet-poor plasma, which removes the cellular contributions of platelets, erythrocytes, and leukocytes. This design limitation explains why prothrombin time (PT) and activated partial thromboplastin time (aPTT) cannot detect hypercoagulable states or disorders of fibrinolysis, as noted in the point of care assessment of coagulation.

The coagulation cascade is conventionally divided into the extrinsic pathway (tissue factor and factor VII), the intrinsic pathway (factors XII, XI, IX, VIII), and the common pathway (factors X, V, II, fibrinogen). PT assesses the extrinsic and common pathways after addition of tissue factor and phospholipid. aPTT assesses the intrinsic and common pathways after contact activation. Both tests end at fibrin clot formation and provide no information about clot strength, stability, or degradation.

Preanalytical Variables and Sample Handling

Sample quality determines result validity more than any analytic factor. Blood must be collected by atraumatic venipuncture into 3.2% sodium citrate at a ratio of nine parts blood to one part citrate. Underfilled tubes alter the citrate concentration and prolong clotting times artifactually. Hemolyzed, lipemic, or clotted samples should be rejected.

Plasma stability varies by analyte. In canine plasma stored at 4°C, aPTT prolongs significantly after 72 hours, factors VIII and IX decrease after 48 hours, and factor XI decreases after 72 hours, while PT, fibrinogen, antithrombin, and D-dimer remain stable for up to 96 hours according to a study of stored canine plasma for hemostasis testing. These findings mandate prompt analysis or appropriate freezing for delayed testing. Point-of-care devices reduce turnaround time but introduce operator-dependent variability and device-specific analytic performance differences compared with reference laboratory instruments, as described in the point of care assessment of coagulation.

Conventional Coagulation Tests

Prothrombin Time

PT is the first test to prolong in anticoagulant rodenticide toxicity because factor VII has the shortest half-life among vitamin K-dependent factors. It is also prolonged in liver failure, vitamin K deficiency, and disseminated intravascular coagulation (DIC). A normal PT with prolonged aPTT suggests an intrinsic pathway defect such as hemophilia A or B, which are X-linked disorders affecting factor VIII and IX respectively.

Activated Partial Thromboplastin Time

aPTT prolongation occurs with intrinsic pathway factor deficiencies, heparin therapy, and DIC. Combined prolongation of PT and aPTT indicates common pathway involvement, multiple factor deficiencies, or severe liver disease. Isolated aPTT prolongation in a young male dog should prompt specific factor assays for hemophilia, though these are beyond the scope of this article.

Activated Clotting Time

The activated clotting time (ACT) is a whole blood test that evaluates the intrinsic and common pathways. It is less sensitive than aPTT and requires significant factor depletion before prolongation occurs. ACT is useful for monitoring heparin therapy and as a rapid screening test in emergency settings where laboratory support is unavailable.

Viscoelastic Coagulation Testing

Viscoelastic methods such as thromboelastography and rotational thromboelastometry assess global coagulation using whole blood, capturing the interaction between platelets, coagulation factors, and fibrinolytic enzymes. These techniques provide information about clot initiation, propagation, maximum strength, and lysis, and can detect hypercoagulability that conventional tests miss, as reviewed in viscoelastic coagulation testing technology applications and limitations.

Clinical applications include preoperative assessment, monitoring of anticoagulant therapy, and characterization of hypercoagulable states. In dogs with hyperadrenocorticism, comprehensive coagulation testing including viscoelastic methods identified a hypercoagulable tendency in 88.2% of affected dogs, though abnormalities in one assay did not predict abnormalities in others, according to a study of coagulation in canine hyperadrenocorticism. This finding underscores the value of global testing over single assays.

Platelet Function and Primary Hemostasis

Platelet function testing addresses disorders that conventional coagulation tests cannot detect. Point-of-care platelet function analyzers can identify adhesion defects including von Willebrand disease and monitor antiplatelet drug efficacy, as described in the point of care assessment of coagulation. Buccal mucosal bleeding time remains a practical bedside test but is operator-dependent and insensitive to mild defects.

Thrombocytopenia itself can cause clinical bleeding without any coagulopathy. In cattle, acute bovine viral diarrhea virus infection produced platelet counts from 2,000 to 33,000/microliters with bleeding manifested as bloody diarrhea, petechiation, epistaxis, and injection site hemorrhage, while coagulation testing in six cases showed no evidence of DIC, as reported in a case series of thrombocytopenia with acute BVDV infection. This distinction between thrombopathic and coagulopathic bleeding guides both diagnostic testing and treatment decisions.

Diagnostic Approach to the Bleeding Patient

The clinical presentation determines the pace and extent of coagulation testing. A bleeding patient with acute deterioration requires immediate point-of-care assessment, while a patient with chronic or mild bleeding allows a more deliberate laboratory workup. The first decision is whether bleeding is due to a platelet disorder, a coagulation factor defect, or a combination of both.

Petechiae and mucosal surface bleeding point toward thrombocytopenia or platelet dysfunction. Deep hematomas, hemarthrosis, and body cavity hemorrhage point toward factor deficiency or consumption. This distinction guides initial test selection. A platelet count and blood smear evaluation should accompany any coagulation panel, since thrombocytopenia is a common cause of bleeding and will alter interpretation of clotting times.

The timing of bleeding relative to a known insult matters. Bleeding that begins hours after trauma or surgery suggests a factor deficiency or acquired coagulopathy. Bleeding that begins immediately after tissue injury suggests a vascular or platelet defect. A patient with anticoagulant rodenticide toxicity typically presents 3 to 5 days after exposure, and the onset is often delayed until factor stores are depleted.

Initial Assessment and Test Selection

The minimum database for a bleeding patient includes a platelet count, blood smear, packed cell volume or hematocrit, total protein, and a coagulation panel. The panel should include prothrombin time (PT) and activated partial thromboplastin time (aPTT). These two tests together screen the extrinsic and intrinsic pathways and the common pathway.

A prolonged PT with a normal aPTT suggests factor VII deficiency or early anticoagulant rodenticide toxicity. A prolonged aPTT with a normal PT suggests an intrinsic pathway defect such as hemophilia A or B, or factor XII deficiency. Prolongation of both tests indicates common pathway involvement, severe liver disease, disseminated intravascular coagulation (DIC), or advanced rodenticide toxicity. Normal PT and aPTT with active bleeding should prompt evaluation of platelet function, von Willebrand factor, or a vascular disorder.

The activated clotting time (ACT) is a useful screening test when laboratory-based PT and aPTT are unavailable. It is insensitive to mild factor deficiencies and does not detect platelet disorders, but it can identify moderate to severe coagulopathies. The ACT is prolonged when factor activity falls below approximately 5% of normal, which is later in the course of rodenticide toxicity than PT prolongation. Point of care coagulation assessment can provide rapid results but has limitations in sensitivity compared with reference laboratory methods.

Species-Specific Considerations

Test selection and interpretation differ by species. Dogs are the most commonly tested companion animal, and canine reference intervals are well established. Cats present a particular challenge because their blood is more difficult to collect cleanly, and their platelets are larger and more prone to clumping. A falsely low platelet count from clumping is a common artifact in feline samples.

Cattle with acute bovine viral diarrhea virus infection can develop severe thrombocytopenia with platelet counts as low as 2,000 to 33,000 per microliter, and affected animals may show bloody diarrhea, petechiae, epistaxis, or bleeding from injection sites. Coagulation testing in six of these cases showed no evidence of DIC, indicating that the bleeding was primarily platelet-mediated. Thrombocytopenia associated with acute BVDV infection should be considered in any adult bovine presenting with unexplained hemorrhage.

Horses require larger sample volumes and are prone to sample activation during venipuncture. Foals with failure of passive transfer may develop sepsis-associated coagulopathy. Small ruminants and camelids have reference intervals that differ from those of cattle, and few validated point-of-care devices exist for these species.

Mice and other laboratory species have strain-specific coagulation phenotypes, and automated analyzers require adaptation for small sample volumes. High-throughput coagulation screening in mice has demonstrated considerable variation among inbred strains, which matters for research applications but has limited direct relevance to clinical practice.

Interpreting Coagulation Panels in Context

Coagulation test results must be interpreted in light of the platelet count, liver function, and the patient's clinical status. A prolonged PT or aPTT does not confirm a bleeding disorder unless the patient is actually bleeding or the prolongation is severe. Factor activities must fall below approximately 30% of normal before clotting times prolong, and clinically significant bleeding usually requires factor activity below 10%.

Hypercoagulability and Thrombotic Risk

Standard coagulation tests cannot detect hypercoagulability. PT and aPTT measure clot formation in platelet-poor plasma and provide no information about platelet function, fibrinolysis, or the balance of procoagulant and anticoagulant forces. Viscoelastic coagulation testing evaluates whole blood clot formation from initiation through fibrinolysis and can identify hypercoagulable states that conventional tests miss.

Dogs with hyperadrenocorticism frequently show a hypercoagulable tendency. In one prospective study, 88.2% of dogs newly diagnosed with hyperadrenocorticism exhibited hypercoagulability on comprehensive coagulation testing, but abnormalities in one assay did not predict abnormalities in another. Coagulation assessment in canine hyperadrenocorticism supports the use of a panel approach instead of reliance on a single test when assessing thrombotic risk.

Monitoring Anticoagulant Therapy and Rodenticide Toxicity

Serial PT measurement is the standard method for monitoring anticoagulant rodenticide toxicity. The PT prolongs before clinical bleeding develops, and serial measurements document response to vitamin K therapy. Treatment should continue until the PT remains normal for 48 to 72 hours after vitamin K withdrawal.

For patients receiving heparin therapy, the aPTT or anti-factor Xa activity is used for monitoring. The aPTT is more widely available but is affected by reagent and analyzer variability. Anti-factor Xa assays provide more consistent results but are not available at all reference laboratories.

Sample Artifacts and Troubleshooting

Plasma stability studies in dogs show that PT, factors II, V, VII, X, and XII, D-dimer, and antithrombin remain stable for up to 96 hours at 4 degrees Celsius. In contrast, aPTT prolongs after 72 hours, fibrinogen decreases after 48 hours at room temperature, and factors VIII, IX, and XI degrade progressively. Stability of stored canine plasma supports prompt separation and refrigeration of plasma when immediate analysis is not possible.

Documentation and Reporting

Coagulation results should be recorded with the collection time, sample quality, analyzer used, and reference interval for that analyzer. Results from point-of-care devices are not interchangeable with reference laboratory values, and the device used should be noted in the medical record. ASVCP quality assurance guidelines emphasize that reference intervals must be validated for the specific method and population.

When results are borderline or inconsistent with the clinical picture, repeat testing is appropriate before making treatment decisions. A single prolonged clotting time in a stable patient warrants confirmation, particularly if the sample was difficult to collect or the history suggests possible artifact.

Test Selection by Clinical Scenario

The choice of tests depends on the equipment available, the species, and the clinical question. A practice with only an ACT device can identify severe coagulopathies but will miss mild factor deficiencies and all hypercoagulable states. Referral to a laboratory with viscoelastic capability is appropriate when hypercoagulability is suspected or when global hemostatic assessment is needed. Point of care coagulation testing is unlikely to be replaced by a single device that assesses all aspects of hemostasis, so the test panel must be tailored to each patient.

Recognized Complications and Failure Modes

Coagulation testing fails clinically when results do not match the patient's phenotype. The most consequential failure mode is a normal panel in a bleeding patient. This occurs when the defect lies in primary hemostasis, fibrinolysis, or a factor below the detection threshold of the screening tests. Platelet function testing and viscoelastic methods should be pursued when PT and aPTT are normal but hemorrhage continues point of care assessment of coagulation.

A second failure mode is the false diagnosis of disseminated intravascular coagulation based on a single prolonged clotting time with thrombocytopenia. Acute BVDV infection in cattle can produce severe thrombocytopenia with bleeding manifestations while coagulation testing shows no evidence of consumptive coagulopathy thrombocytopenia associated with acute bovine virus diarrhea infection in cattle. The discriminating feature is the platelet count trend and the absence of concurrent prolongation of multiple clotting times.

Sample-related failure modes are common and preventable. Underfilled citrate tubes alter the citrate-to-blood ratio and prolong clotting times. Hemolyzed samples falsely elevate some results and degrade others. Delayed separation of plasma allows progressive factor consumption, particularly of labile factors VIII and IX. Stored canine plasma shows that aPTT prolongs after 72 hours at 4 degrees C and factor VIII and IX activities decline by 48 hours, so samples must be processed promptly or frozen stability of stored canine plasma for hemostasis testing.

Common Errors and Corrective Actions

Less experienced clinicians often test too early or too late. Testing before any anticoagulant or transfusion has been given is essential for diagnosis. Testing after plasma transfusion reflects the transfusion, not the patient. The corrective action is to collect coagulation samples before intervention whenever the clinical situation permits.

A second error is overinterpreting a single mildly prolonged value. Reference intervals are population-based, and mild prolongation may reflect analytic variation or a borderline sample. Repeat the test, confirm the abnormality, and correlate with physical examination findings before committing to a diagnosis. The ASVCP quality assurance guidelines emphasize that reference intervals must be validated for the instrument and reagent system in use ASVCP quality assurance and laboratory standards guidelines.

A third error is using conventional clotting times to assess hypercoagulability. PT and aPTT are performed on platelet-poor plasma and cannot detect a hypercoagulable tendency. Dogs with hyperadrenocorticism frequently show hypercoagulability on comprehensive testing, but this is not reliably identified by standard clotting times assessment of coagulation and potential biochemical markers for hypercoagulability in canine hyperadrenocorticism. Viscoelastic testing is the appropriate method when thrombotic risk is the clinical question viscoelastic coagulation testing technology applications and limitations.

Limitations of Current Evidence

The evidence base for coagulation testing in veterinary medicine is uneven across species. Canine data are the most extensive, followed by feline and equine. Data for cattle, small ruminants, and exotic species are largely extrapolated from other species or derived from small case series. The thrombocytopenia associated with acute BVDV infection, for example, is documented in a case series of 146 cattle, but the pathogenesis was not definitively determined thrombocytopenia associated with acute bovine virus diarrhea infection in cattle.

Expert opinion still differs on the clinical utility of viscoelastic testing. Some specialists advocate its routine use in surgical and critically ill patients, while others reserve it for cases where conventional testing is unrevealing. The technology provides global assessment of clot formation and fibrinolysis, but standardization of reagents and interpretation criteria across institutions remains incomplete viscoelastic coagulation testing technology applications and limitations.

Reference intervals for coagulation parameters vary by breed, age, and analyzer platform. Inbred mouse strains show considerable variation in coagulation phenotypes, and similar variation is presumed in domestic species large-scale high-throughput screening for coagulation and hematologic phenotypes in mice. Clinicians should use intervals established for their own laboratory and patient population.

Referral, Consultation, and Reporting

Referral is warranted when a bleeding disorder cannot be characterized despite appropriate testing, when hemorrhage is refractory to standard therapy, or when a hereditary coagulopathy is suspected and factor analysis is needed. Specialist consultation with a veterinary clinical pathologist is appropriate for difficult interpretations, method validation questions, or unusual species.

Laboratory involvement is required when results are inconsistent with the clinical picture, when quality control failures are suspected, or when a new test method is being introduced. The ASVCP guidelines provide a framework for method validation, quality control, and reference interval establishment ASVCP quality assurance and laboratory standards guidelines.

Regulatory reporting obligations vary by jurisdiction. Suspected anticoagulant rodenticide toxicity may carry reporting requirements in some regions. Notifiable diseases that cause hemorrhage, such as certain viral hemorrhagic fevers, must be reported according to local and international animal health standards WOAH terrestrial animal health standards. Clinicians should be familiar with the requirements of their own regulatory authority.

Frequently Asked Questions

How should I prioritize coagulation testing when cost or sample volume is limited?

Start with the tests that most directly answer the clinical question. For a bleeding patient, a platelet count, packed cell volume, and blood smear evaluation are inexpensive and often diagnostic. If a coagulopathy is suspected, run an activated clotting time (ACT) at the cage side or submit citrated plasma for PT and aPTT. When only one conventional test can be performed, choose based on the bleeding pattern. Petechiae and mucosal bleeding suggest primary hemostasis defects, so platelet evaluation takes priority. Deep hematomas or joint bleeding point toward secondary hemostasis, making PT or aPTT more useful. Viscoelastic testing offers broader information but carries higher cost and requires operator training, as noted in point of care coagulation assessment. Reserve it for cases where standard tests are unrevealing or where hypercoagulability is the primary concern.

What can I do when viscoelastic testing is unavailable?

Conventional tests remain clinically valuable. PT and aPTT detect hypocoagulability reliably, and ACT provides a rapid cage-side alternative when laboratory access is delayed. Platelet function testing, where available, identifies adhesion defects such as von Willebrand disease. When these options are absent, rely on serial platelet counts, blood smear evaluation for schistocytes and platelet morphology, and careful clinical assessment of bleeding progression. Antithrombin activity and D-dimer concentration can be measured on stored frozen plasma at a reference laboratory and may support a hypercoagulability diagnosis, although their predictive value in individual patients is limited. The stability of stored canine plasma for hemostasis testing supports freezing samples for later analysis when immediate testing is impossible. Document the limitations of your testing approach in the medical record.

How do I interpret a prolonged aPTT with a normal PT in a dog?

This pattern localizes the defect to the intrinsic or common pathway. Differential diagnoses include heparin contamination, factor VIII or IX deficiency, and acquired inhibitors. Hemophilia A or B should be suspected in young male dogs with a history of bleeding, but factor assays are required for confirmation. Heparin contamination from an indwelling catheter is a common artifact, so confirm the sample was collected cleanly. In a hospitalized patient, consider whether the sample was stored before analysis, because aPTT prolongs after 72 hours of refrigeration in canine plasma while PT remains stable, as shown in canine plasma stability research. Repeat the test on a fresh sample before pursuing extensive factor analysis. If the prolongation persists and no explanation is found, consult a specialist for factor assays and inhibitor screening.

When should I suspect hypercoagulability instead of hypocoagulability?

Hypercoagulability presents with thrombosis instead of bleeding. Clinical clues include unexplained pulmonary thromboembolism, aortic thromboembolism in cats, or recurrent venous thrombosis. Diseases associated with hypercoagulability include hyperadrenocorticism, immune-mediated hemolytic anemia, protein-losing nephropathy, and neoplasia. In dogs with hyperadrenocorticism, the majority show a hypercoagulable tendency on comprehensive testing, but abnormalities in one assay do not predict abnormalities in another, according to coagulation assessment in canine hyperadrenocorticism. Conventional tests such as PT and aPTT cannot detect hypercoagulability. Viscoelastic testing is better suited for this purpose, as described in viscoelastic coagulation technology. If viscoelastic testing is unavailable, document the clinical risk factors and consider prophylactic therapy based on the underlying disease.

How should I handle coagulation testing in cattle and other large animals?

Sample handling principles are similar across species, but reference intervals differ. Bovine platelets are more reactive in vitro, so gentle venipuncture and prompt mixing with citrate are essential. Acute bovine viral diarrhea virus infection can cause severe thrombocytopenia with bleeding manifesting as bloody diarrhea, petechiae, and epistaxis, as reported in thrombocytopenia with acute BVDV infection. Coagulation testing in those cases showed no evidence of disseminated intravascular coagulation, so a normal PT and aPTT does not exclude a bleeding disorder when thrombocytopenia is present. For horses, sample promptly because platelet activation occurs quickly. Always use species-specific reference intervals and consult MSD Veterinary Manual guidance for species-specific coagulation values. When in doubt, submit samples to a laboratory with established reference intervals for that species.

What should I document when coagulation testing is performed?

Record the indication for testing, the specific tests ordered, collection time and method, and any preanalytical issues such as a difficult venipuncture or clotted sample. Note the analyzer and reagent used if point-of-care testing was performed, because results may differ from reference laboratory methods. Document the reference interval used and whether the result was interpreted against a species-specific interval. If samples were frozen for later analysis, record the storage conditions and duration. Include your interpretation in the context of the clinical presentation, not as an isolated number. For cases where testing was limited by cost or equipment, state this explicitly. The ASVCP quality assurance guidelines provide a framework for documenting method validation and quality control that supports defensible medical records.

Related Clinical & Scientific Guides

• Peripheral Blood Smear Evaluation: A Step-by-Step Guide
• Reticulocyte Counts in Veterinary Medicine: Clinical Utility and Interpretation
• Cerebrospinal Fluid Analysis in Veterinary Neurology: Collection and Interpretation

References and Further Reading

• Thrombocytopenia associated with acute bovine virus diarrhea infection in cattle.. 1989.
• Assessment of coagulation and potential biochemical markers for hypercoagulability in canine hyperadrenocorticism.. 2013.
• Point of Care Assessment of Coagulation.. 2016.
• Stability of stored canine plasma for hemostasis testing.. 2006.
• Viscoelastic coagulation testing: technology, applications, and limitations.. 2011.
• Large-scale, high-throughput screening for coagulation and hematologic phenotypes in mice.. 2002.
• American Society for Veterinary Clinical Pathology Guidelines. American Society for Veterinary Clinical Pathology.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.
• American Veterinary Medical Association Practice Resources. American Veterinary Medical Association.

Related Articles

• Quality Control in Veterinary Laboratory Testing: A Practical Guide
• Point-of-Care Testing in Veterinary Practice: Benefits and Limitations
• Reticulocyte Counts in Veterinary Medicine: Clinical Utility and Interpretation
• Electrolyte and Acid-Base Disturbances: A Practical Interpretation Guide
• Monitoring Coagulation Status in Anticoagulant Rodenticide Toxicity

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.